Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma. The company is actively expanding its global footprint with ongoing trials in the United States, Asia, and other regions. Partnerships and collaborations with academic institutions and pharmaceutical companies support the clinical development and potential commercialization of its lead candidate. In addition to NBTXR3, Nanobiotix continues to explore next-generation nanotherapies and combination strategies aimed at enhancing standard oncology protocols.

Founded in 2003 by Dr. Laurent Levy and a team of researchers, Nanobiotix combines expertise in physics, chemistry and oncology to address unmet needs in cancer care. The company maintains R&D facilities in Europe and the United States and is led by Dr. Levy, who serves as Chief Executive Officer. Through its science-driven approach, Nanobiotix seeks to deliver safer, more effective treatment options for patients worldwide and to transform the way radiotherapy is applied in solid tumor oncology.

Key Stats

• Today's Range: $31.68 to $36.15
• 50-Day Range: $29.95 to $55.07
• 52-Week Range: $4.18 to $57.14
• Volume: 73,772 shs
• Average Volume: 59,091 shs
• Market Capitalization: $1.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.33
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 52% of companies evaluated by MarketBeat, and ranked 549th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Nanobiotix is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Nanobiotix has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 231.58%

Earnings Growth

Earnings for Nanobiotix are expected to grow by 231.58% in the coming year, from $0.19 to $0.63 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 114.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Nanobiotix this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for NBTX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

38.81% of the stock of Nanobiotix is held by institutions.

Company Calendar

• Last Earnings: 2/15/2026
• Today: 6/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NBTX
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 100
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Nanobiotix: $37.33
• High Price Target: $46.00
• Low Price Target: $30.00
• Potential Upside/Downside: +11.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.09
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $36.87 million
• Price / Sales: 44.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -16.99

Miscellaneous

• Outstanding Shares: 48,520,000
• Free Float: 46,844,000
• Market Cap: $1.62 billion
• Optionable: Not Optionable
• Beta: 0.73